Consultation on Notifying the FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act (Catapult’s regulatory round-up – february 2024)
| Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act | End date: open | Draft Guidance |
Published on the 5th of March 2024 in Catapult’s regulatory round-up for february 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (5 novembre 2024). Consultation on Notifying the FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act (Catapult’s regulatory round-up – february 2024). ELSIBI. Consulté le 10 décembre 2024 à l’adresse https://doi.org/10.58079/12mip
